Abstract
The intramolecularly coordinated phosphine and stibine ligands L1PPh2 (1), L2PPh2 (2) and L2SbPh2 (3) containing Y,C,Y‐chelating ligands, L1 = 2,6‐(tBuOCH2)2C6H4− and L2 = 2,6‐(Me2NCH2)2C6H4−, were prepared and characterized. The treatment of these ligands 1, 2, 3 with PtCl2 yielded complexes trans‐{[2,6‐(tBuOCH2)2C6H3]PPh2}2PtCl2 (4), cis‐{[2,6‐(Me2NCH2)2C6H3]PPh2}PtCl2 (5), and cis‐{[2,6‐(Me2NCH2)2C6H3]SbPh2}PtCl2 (6) as the result of different ability of the starting compounds 1, 2, 3 to complex platinum centre. Compounds 1, 2, 3, 4, 5, 6 were characterized by 1H, 13C and 31P NMR spectroscopy and electrospray ionization mass spectrometry, and molecular structures of 3, 4, 5, 6 were determined by X‐ray diffraction analysis. The substitution reactions of complexes 4, 5, 6 were also studied. The reaction of 5 and 6 with NaI yielded complexes {[2,6‐(Me2NCH2)2C6H3]PPh2}PtI2 (7) and {[2,6‐(Me2NCH2)2C6H3]SbPh2}PtI2 (8), while the same reaction of 4 with NaI did not proceed. As the compounds 7 and 8 structurally resemble cisplatin, complex {{[2‐(Me2NCH2)‐6‐(Me2NHCH2)C6H3]PPh2}PtCl2}+Cl− (9) was prepared as water‐soluble platinum complex. The cytotoxic effect of complex 9 was evaluated on human T‐lymphocytic leukemia cells MOLT‐4 (IC50 = 27.6 ± 1.8 µmol l−1) and human promyelocytic leukemia HL‐60 (IC50 = 55.9 ± 4.9 µmol l−1). Copyright © 2012 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
